natgillin/translations-raw huggingface dataset:
Uncommon side effects difficulty breathing, decrease in level of oxygen, choking, swelling of the airways, fluid in airways, shortness of breath during physical activity, wheezing, coughing up more phlegm, coughing up blood, stuffy nose lung infection, sinus infection chest pain or heart attack, high blood pressure or low blood pressure, chest discomfort abnormal blood test results, including increase in white blood cells, low potassium levels bleeding, loss of blood, increased tendency to bruise over development of breasts in men, inability to urinate, temperature intolerance, cold sweats, night sweats general swelling, general pain, musculoskeletal chest pain, stiffness of joint, inflammation of the heel shakes, restlessness, dizziness, numbness, flushes, feeling weak, feeling unwell loss of hearing, ringing in the ears, swelling of the eye, eye pain rash, redness at the injection site, nail fungal infection, skin infection, blister, itchy skin, overgrowth of tissue at the site of skin injury, scar pain, scab, presence of skin moles, abnormal hair growth 
- oteženo dihanje, izkašljevanje krvi, znižanje ravni kisika, dušenje, zatekanje dihalnih poti, tekočina v dihalnih poteh, kratka sapa med naporom, sopenje, izkašljevanje več sluzi, izkašljevanje krvi, zamašen nos. - vnetje pljuč, vnetje sinusov.
STATEMENT OF ACTIVE SUBSTANCE(S) One vial contains 75 mg porfimer sodium 
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Ena viala vsebuje 75 mg porfimer-natrija.
− Area in card for physician to record skin type and date of injection. 
− V bolnikovi izkaznici je predviden prostor, v katerega zdravnik vnese tip kože in
Keep the vial in the outer carton in order to protect from light After reconstitution, protect from light and use immediately within 3 hours. 
Po pripravi je treba raztopino PhotoBarra zaščititi pred svetlobo in uporabiti v 3 urah.
Hiccups, odynophagia, diarrhoea, dyspepsia, oesophageal ulcer, abdominal pain upper*, abdominal pain, haematemesis, oesophageal pain, eructation, melaena (haematocheznia), oesophageal disorder, regurgitation of food, abdominal rigidity, oesophageal spasm, oesophagitis. 
Kolcanje, odinofagija, diareja, dispepsija, razjeda požiralnika, bolečine v zgornjem delu trebuha*, bolečine v trebuhu, hematemeza, bolečina v požiralniku, kolcanje, melena, bolezen požiralnika, bljuvanje hrane, trd trebuh, krč požiralnika, vnetje požiralnika (ezofagitis).
PACKAGE LEAFLET: INFORMATION FOR THE USER PhotoBarr 75 mg powder for solution for injection Porfimer sodium 
PhotoBarr 75 mg prašek za raztopino za injiciranje Porfimer-natrij
Ear and labyrinth disorders Uncommon: 
Ušesne bolezni, vključno z motnjami labirinta Občasne:
Embolism, Deep vein thrombosis, Phlebitis Respiratory, thoracic and mediastinal disorders Common: 
Bolezni dihal, prsnega koša in mediastinalnega prostora Pogoste:
Reproductive system and breast disorders Uncommon: 
Motnje reprodukcije in dojk Občasne:
EXPIRY DATE 
Zahtevana izhodna
In patients,the mean peak plasma concentration (Cmax) was 79.6 μg/ml (C.V. 61%, range 39-222), whereas in volunteers Cmax was 40 μg/ml and AUCinf was 2400 μg/h/ml. 
Pri bolnikih je bila največja /koncentracija v plazmi (Cmax) takoj po injiciranju 79,6 μg/ml (C.V.
Do not use after the expiry date stated on the carton and vial after the EXP. Do not store above 25°C. 
Zravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatlici in viali za oznako EXP.
The European Commission granted a marketing authorisation valid throughout the European Union for ProteqFlu on 6 March 2003. 
Evropska komisija je dovoljenje za promet z zdravilom ProteqFlu, veljavno po vsej Evropski uniji, izdala 6. marca 2003.
Equine influenza is a highly contagious disease that is very common in horses but rarely causes death. 
Konjska influenca je zelo nalezljiva bolezen, ki je zelo pogosta pri konjih, vendar redko povzroči pogin.
The effectiveness of ProteqFlu was first assessed in several laboratory and field studies. 
Učinkovitost cepiva ProteqFlu so najprej ocenili v več laboratorijskih in terenskih študijah.
The duration of protection was 5 months after primary vaccination and one year after the third vaccination. 
Trajanje zaščite je bilo 5 mesecev po primarnem cepljenju in eno leto po tretjem cepljenju.
The immunogenicity of the current formulation of the vaccine was confirmed in 15 foals. 
Imunogenost trenutne formulacije cepiva je bila potrjena pri 15 žrebetih.
In case of increased risk of infection or insufficient intake of colostrum (first milk), an additional initial injection can be given at the age of 4 months, followed by the full vaccination programme (primary vaccination and following revaccinations). 
V primeru povečanega tveganja okužbe ali nezadostnega zaužitja kolostruma (prvega mleka), se lahko injicira dodatni začetni odmerek pri starosti 4 mesecev, ki mu sledi popoln program cepljenja (primarno cepljenje, ki mu sledijo ponovitve).
Horses should receive a primary vaccination, consisting of two injections at 5-6 months of age, given 4-6 weeks apart. 
Konji potrebujejo primarno cepljenje, ki vključuje dve injiciranji pri starosti 5-6 mesecev in se ju izvede 4-6 tednov narazen.
Other information about ProteqFlu: 
Druge informacije o zdravilu ProteqFlu:
This means that a gene from two different equine influenza strains (A/eq/Ohio/03 and A/eq/Richmond/1/07) was inserted into the canarypox vector viruses, which do not produce disease in horses, allowing the vector to produce specific proteins from these influenza strains. 
To pomeni, da je bil gen iz dveh različnih sevov virusa konjske influence (A/eq/Ohio/03 in A/eq/Richmond/1/07) vstavljen v viruse vektorja canarypox, ki pri konjih ne povzroči bolezni, a omogoči vektorju, da proizvede določene beljakovine iz teh sevov influence).
Equine influenza vaccine 
Cepivo proti konjski influenci
The vaccine is given as an intramuscular injection (injection into a muscle). 
Cepivo se daje z intramuskularno injekcijo (vbrizga se v mišico).
A short lived swelling at the injection site may occur (max. diameter 5 cm) which decreases within 4 days. 
Na mestu injiciranja se lahko pojavi kratkotrajna oteklina (največjega premera 5 cm), ki izgine v 4 dneh.
In case of accidental self-injection, medical advice should be sought immediately and the package leaflet or the label shown to the doctor. 
V primeru nenamernega samoinjiciranja je treba takoj poiskati zdravniško pomoč in zdravniku pokazati navodilo za uporabo ali nalepko.
This should be followed by revaccination 5 months later and afterwards by yearly booster vaccinations. 
Temu mora slediti ponovno cepljenje po 5 mesecih in nato letna poživitvena cepljenja.
What benefit has ProteqFlu shown during the studies? 
Kakšne koristi je zdravilo ProteqFlu izkazalo med študijami?
ProteqFlu contains an adjuvant (carbomer) to enhance the immune response. 
Zdravilo ProteqFlu vsebuje adjuvans (karbomer)za povečanje imunskega odziva.
ProteqFlu is a vaccine for use in horses. 
Zdravilo ProteqFlu je cepivo, ki se uporablja pri konjih.
The measure of effectiveness in all studies was antibody levels against the two influenza vaccine strains. 
Merilo učinkovitosti v vseh študijah je bila raven protiteles proti obema sevoma virusa konjske influence.
ProteqFlu is a vaccine which was produced with the use of recombinant DNA technology. 
Zdravilo ProteqFlu je cepivo, ki je bilo izdelano s tehnologijo rekombinantne DNK.
The withdrawal period for ProteqFlu for meat and milk is zero days. 
Karenca za cepivo ProteqFlu za meso in mleko je nič dni.
It contains parts of two equine influenza (flu) strains, which have been inserted into two canarypox vector (carrier) viruses respectively. 
Vsebuje dele dveh sevov virusa konjske influence (gripe), vstavljenih v dva virusa vektorja (prenašalca) canarypox.
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of ProteqFlu exceed the risks for the approved indication and recommended that ProteqFlu be given a marketing authorisation. 
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi cepiva ProteqFlu večje od z njim povezanih tveganj, kadar se uporablja za odobrene indikacije, in priporočil, da se zanj izda dovoljenje za promet.
ProteqFlu is available as a suspension for injection. 
Zdravilo ProteqFlu je na voljo v obliki suspenzije za injiciranje.
The current formulation of ProteqFlu produced similar antibody responses against the two flu strains included in the vaccine to those seen in the main studies. 
Trenutna formulacija cepiva ProteqFlu je sprožila podobne odzive protiteles proti obema sevoma influence, vključenima v cepivo, kot so bili tisti v glavnih študijah.
What is the risk associated with ProteqFlu? 
Kakšna tveganja so povezana z zdravilom ProteqFlu?
The studies showed that ProteqFlu was effective in reducing clinical signs and virus excretion after infection with equine influenza, 14 days after primary vaccination. 
Študije so pokazale, da je bilo cepivo ProteqFlu pri zmanjševanju kliničnih znakov in izločanju virusa po okužbi s konjsko influenco učinkovito 14 dni po primarnem cepljenju.
Most of the studies were performed with ProteqFlu-Te, a vaccine that protects against two strains of equine influenza as well as against tetanus. 
Večino študij so izvedli s cepivom ProteqFlu-Te, cepivom za zaščito proti dvema sevoma virusa konjske influence in proti tetanusu.
In laboratory studies, horses were challenged (infected) with equine influenza virus and the clinical signs and the excretion of the influenza virus after the challenge were compared between vaccinated and control animals (non-vaccinated animals or those vaccinated with a competitor product). 
Klinične znake in izločanje virusa influence po okužbi so primerjali med cepljenimi in kontrolnimi živalmi (živali, ki niso bile cepljene ali cepljene s konkurenčnim cepivom).
ProteqFlu is used to vaccinate horses from 4 months of age against equine influenza. 
Zdravilo ProteqFlu se uporablja za cepljenje konj, starejših od štirih mesecev, proti konjski influenci.
When ProteqFlu is given to horses, the animals' immune system recognises the specific proteins from the equine influenza strains as ‘foreign' and makes antibodies against them. 
Ko konji prejmejo cepivo ProteqFlu, imunski sistem živali prepozna določene beljakovine iz sevov virusa konjske influence kot tujke in se nanje odzove s tvorbo protiteles.
The vaccine reduces the clinical signs of equine influenza and the excretion (shedding) of the virus after infection. 
Cepivo ublaži klinične znake konjske influence in izločanje virusa po okužbi.
Why has ProteqFlu been approved? 
Zakaj je bilo zdravilo ProteqFlu odobreno?
The immune system will then be able to make those protective antibodies more quickly when the animal is naturally exposed to the equine flu viruses. 
Imunski sistem bo nato pri naravni izpostavitvi virusom konjske influence sposoben hitreje ustvarjati ta zaščitna protitelesa.
What is ProteqFlu used for? 
Za kaj se zdravilo ProteqFlu uporablja?
This will help to protect against equine influenza. 
To pomaga zaščititi živali proti konjski influenci.
What is ProteqFlu? 
Kaj je zdravilo ProteqFlu?
How does ProteqFlu work? 
Kako zdravilo ProteqFlu deluje?
How has ProteqFlu been studied? 
Kako je bilo zdravilo ProteqFlu raziskano?
There are two options: 
Na voljo sta dve možnosti:
Date of first authorisation: 25 January 2010 Date of latest renewal: 22 August 2014 
Datum prve odobritve: 25. januar 2010 Datum zadnjega podaljšanja: 22. avgust 2014
See Table 1 below. 
Glejte preglednico 1 spodaj.
(See also section 4.2.) 
(Glejte tudi poglavje 4.2.)
(See also section 4.) 
(Glejte tudi poglavje 4.)
Your doctor will advise you at what time you can start performing pregnancy tests. 
Zdravnik vam bo svetoval, kdaj lahko začnete opravljati teste nosečnosti.
The absolute bioavailability is 58% (48-70% 
Njegova absolutna biološka uporabnost je 58 % (od 48 do 70 %
Difference [95% CI] 
Razlika [95 % IZ]
In case of a positive pregnancy test, contact your doctor. 
V primeru pozitivnega testa nosečnosti, obvestite zdravnika.
It should be noted, however, that pregnancy itself also carries an increased risk of thrombosis. 
Treba pa je upoštevati, da tudi sama nosečnost prinaša povečano tveganje za trombozo.
Predicted range for 90% of subjects. 
Napovedani razpon za 90 % preiskovank.
However, the differences were within the predefined equivalence (ENGAGE and ENSURE) or non-inferiority (PURSUE) margins. 
Toda razlike so bile znotraj vnaprej opredeljenih mej enakovrednosti (študiji ENGAGE in ENSURE) ali neinferiornosti (študija PURSUE).
If OHSS develops, standard and appropriate management of OHSS should be implemented and followed. 
Če se OHSS pojavi, je treba uvesti in upoštevati standardne in ustrezne ukrepe za obvladanje OHSS.
who weigh 50 kilograms or more and who are older than 36 years of age. 
ki tehtajo 50 kilogramov ali več in so starejše od 36 let.
Gonadotropic hormones play an important role in human fertility and reproduction. 
Gonadotropni hormoni imajo pomembno vlogo pri človeški plodnosti in razmnoževanju.
The chance of having a side effect is described by the following categories: 
Verjetnost pojava neželenih učinkov je podana z naslednjimi kategorijami:
In general, adequate follicular development is achieved on average by the ninth day of treatment (range 6 to 18 days). 
Na splošno velja, da je zadosten razvoj foliklov dosežen v povprečju do devetega dne zdravljenja (razpon: od 6. do 18. dne).
This trial also provided safety data on the infants born from cryopreserved embryos. 
V tem preskušanju so pridobili tudi podatke o varnosti glede otrok, rojenih iz krioprezerviranih zarodkov.
In the absence of compatibility studies, the medicinal product must not be mixed with other medicinal products. 
Zaradi pomanjkanja študij kompatibilnosti zdravila ne smemo mešati z drugimi zdravili.
(35-42 years of age) 
(starost 35-42 let)
Subcutaneous use (SC) 
subkutana uporaba (s.c.)
Infertility evaluation before starting treatment 
Ocena neplodnosti pred začetkom zdravljenja
Pharmacotherapeutic group: sex hormones and modulators of the genital system, gonadotropins, ATC code: G03GA09 
Farmakoterapevtska skupina: Spolni hormoni in modulatorji genitalnega sistema, gonadotropini oznaka ATC: G03GA09
This is a serious medical condition where the ovaries are overly stimulated and the growing follicles become larger than normal. 
To je resna bolezen, pri kateri so jajčniki prekomerno stimulirani in rastoči folikli postanejo večji kot je normalno.
Dosing during the stimulation cycle 
Odmerjanje med ciklusom stimulacije
Make a note of when you start storing the product out of the refrigerator, and use it within one month of that date. 
Zapišite si datum začetka shranjevanja zdravila zunaj hladilnika in zdravilo porabite v roku enega meseca od tega datuma.
FTET Cycle 1 Ongoing pregnancy Live birth FTET Cycle 2 Ongoing pregnancy Live birth n = number of subjects with the event; N = total number of subjects a 
FTET cikel 1 Potekajoča nosečnost Živo rojstvo FTET cikel 2 Potekajoča nosečnost Živo rojstvo n = število preiskovank z dogodkom; N = celotno število preiskovank a na prenos zarodka
Late OHSS occurs more than 10 days after hCG administration, as a consequence of the hormonal changes with pregnancy. 
Pozni OHSS nastopi več kot 10 dni po prejemu hCG kot posledica hormonskih sprememb v nosečnosti.
(18-36 years of age) 
(starost 18-36 let)
If you have any further questions on the use of this medicine, ask your doctor. 
Če imate dodatna vprašanja o uporabi tega zdravila, se posvetujte z zdravnikom.
Severe OHSS may be life-threatening. 
Hud OHSS je lahko življenjsko nevaren.
No studies on the ability to drive and use machines have been performed. 
Študij o vplivu na sposobnost vožnje in upravljanja strojev niso izvedli.
Less than 50 kg 
Manj kot 50 kg
No clinical studies have been performed in patients with renal insufficiency. 
Klinične študije pri bolnicah z ledvično insuficienco niso bile opravljene.
The relevance of these findings for the clinical use of Elonva is limited. 
Pomembnost teh izsledkov za klinično uporabo zdravila Elonva je omejena.
Treatment with the GnRH-antagonist usually starts 5 to 6 days after the injection of Elonva. 
Zdravljenje z antagonistom GnRH običajno začnemo 5 do 6 dni po injekciji zdravila Elonva.
The chance of having this complication can be reduced by carefully monitoring the number of maturing follicles. 
Verjetnost, da bo nastopil ta zaplet, lahko zmanjšamo s skrbnim spremljanjem števila zorečih foliklov.
Multiple pregnancies carry an increased health risk for both the mother and her babies. 
Večplodne nosečnosti so združene s povečanim tveganjem za zdravje tako matere kot otrok.
Corifollitropin alfa has an elimination half-life of 70 hours (59-82 hours 
Razpolovna doba izločanja korifolitropina alfa je 70 ur (59 do 82 ur
This is thought to be due to differences in parental characteristics (e.g., maternal age, sperm characteristics) and the higher incidence of multiple pregnancies. 
Menijo, da je to posledica razlik v značilnostih staršev (npr. starosti matere, značilnostih sperme) in večje incidence večplodnih nosečnosti.
Corifollitropin alfa does not display any intrinsic LH/hCG activity. 
Korifolitropin alfa nima nobene intrinzične aktivnosti LH/hCG.
*corifollitropin alfa is a glycoprotein produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. 
*Korifolitropin alfa je glikoprotein, izdelan v ovarijskih celicah kitajskega hrčka (CHO) z uporabo tehnologije rekombinantne DNA.
In case of an excessive ovarian response, see the recommendations given in section 4.4 in order to reduce the risk for developing ovarian hyperstimulation syndrome (OHSS). 
Če je odziv jajčnikov premočan, pa glejte priporočila, ki so podana v poglavju 4.4, da boste zmanjšali tveganje za nastanek sindroma hiperstimulacije jajčnikov (OHSS).
Treatment with a GnRH antagonist should be started on stimulation day 5 or day 6 depending on the ovarian response, i.e. the number and size of growing follicles. 
Zdravljenje z antagonistom GnRH je treba začeti na 5. dan stimulacije oziroma na 6. dan, odvisno od odziva jajčnikov, tj. od števila in velikosti rastočih foliklov.
IVF involves collecting the eggs from the ovary, fertilising them in the laboratory, and transferring the embryos into the uterus a few days later. 
Pri IVF zberejo jajčeca iz jajčnikov, jih oplodijo v laboratoriju in nekaj dni pozneje zarodke prenesejo v maternico.
For women having their first cycle of ovarian stimulation, for whom risk factors are only partially known, close observation for early signs and symptoms of OHSS is recommended. 
Pri ženskah, ki imajo prvi ciklus stimulacije jajčnikov in so dejavniki tveganja pri njih le delno znani, pa je priporočljivo pozorno spremljanje glede zgodnjih znakov in simptomov OHSS.
Alanine aminotransferase increased, aspartate aminotransferase increased 
Preiskave občasni zvišanje alanin-aminotransferaze, zvišanje aspartat-aminotransferaze
Do not use this medicine after the expiry date which is stated on the label and outer carton after “EXP” (expiry date). 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki in na škatli poleg oznake EXP (rok uporabnosti).
Results of a small uncontrolled study suggest a higher ovarian response than in combination with a GnRH antagonist. 
Izsledki majhne nenadzorovane študije pa so pokazali večji odziv jajčnikov kot pri uporabi kombinacije z antagonistom GnRH.
Since corifollitropin alfa is not a substrate of cytochrome P450 enzymes, no metabolic interactions with other medicinal products are anticipated. 
Ker pa korifolitropin alfa ni substrat za encime citokroma P450, ni pričakovati nikakršnih presnovnih interakcij z drugimi zdravili.
The steady state volume of distribution is 9.2 L (6.5-13.1 L 
Porazdelitveni volumen v stanju dinamičnega ravnovesja je 9,2 l (od 6,5 do 13,1 l
- A single 150-microgram dose is recommended in women: who weigh more than 60 kilograms, regardless of age. 
- Enkraten odmerek 150 mikrogramov je priporočljiv za ženske: ki tehtajo več kot 60 kilogramov, ne glede na starost.
The pH may have been adjusted with sodium hydroxide and/or hydrochloric acid. 
pH je lahko bil uravnan z natrijevim hidroksidom in/ali klorovodikovo kislino.
Because of the risk of developing OHSS, patients should be monitored for at least two weeks after hCG administration. 
Zaradi tveganja za nastanek OHSS je treba ženske spremljati še najmanj dva tedna po prejemu hCG.
1) and a clearance of 0.13 L/h 
1), očistek znaša 0,13 l/h (od
The injection may be given by a healthcare professional (for example a nurse), your partner or yourself, if carefully instructed by your doctor. 
Injekcijo vam bo lahko dal zdravstveni delavec (na primer medicinska sestra) ali vaš partner oziroma si jo boste dali sami, če vam je zdravnik dal natančna navodila za to.
OHSS may be caused by administration of hCG and by pregnancy (endogenous hCG). 
OHSS lahko povzročita uporaba hCG in nosečnost (endogeni hCG).
Reproduction toxicology studies in rats and rabbits indicated that corifollitropin alfa does not adversely affect fertility. 
Toksikološke študije razmnoževanja pri podganah in kuncih so pokazale, da korifolitropin alfa ne vpliva negativno na plodnost.
Not known (cannot be estimated from available data) - Allergic reactions (hypersensitivity reactions, both local and generalised, including rash). 
Neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti) - alergijske reakcije (preobčutljivostne reakcije, tako lokalne kot generalizirane, vključno z izpuščajem).
Both embryotoxicity and teratogenicity are considered a consequence of the superovulatory state of the animal not able to support a number of embryos above a physiological ceiling. 
Vendar bi tako embriotoksičnost kot teratogenost lahko šteli za posledici superovulatornega stanja živali, katerih telo ni moglo vzdrževati števila zarodkov nad fiziološko zgornjo mejo.
One of these gonadotropic hormones is follicle-stimulating hormone (FSH), which is needed in women for the growth and development of follicles (small round sacs in your ovaries that contain the eggs). 
Eden od teh gonadotropnih hormonov je folikle stimulirajoči hormon (FSH), ki je pri ženskah potreben za rast in razvoj foliklov (majhnih, okroglih vrečic v jajčnikih, v katerih so jajčeca).
Stimulation day 5 or 6: 
5. ali 6. dan stimulacije:
In women with generally recognized risk factors for thromboembolic events, such as a personal or family history, severe obesity or thrombophilia, treatment with gonadotropins may further increase this risk. 
Pri ženskah, ki imajo splošno priznane dejavnike tveganja za tromboembolične pojave, na primer pri tistih s tromboembolični pojavi v osebni ali družinski anamnezi, hudo debelostjo ali trombofilijo, lahko zdravljenje z gonadotropini dodatno poveča omenjeno tveganje.
In women undergoing ART procedures the risk of multiple pregnancy is mainly related to the number of embryos transferred. 
Pri ženskah v programu asistirane reprodukcije je tveganje za večplodno nosečnost povezano predvsem s številom prenesenih zarodkov.
<Justification for not including Braille accepted> 
<Sprejeta je utemeljitev, da Braillova pisava ni potrebna>
FTET Cycles of ENGAGE 
FTET cikli študije ENGAGE
Multiple pregnancies and specific characteristics of couples with fertility problems (e.g., a woman's age, certain sperm problems, genetic background of both parents) may also be associated with an increased chance of birth defects. 
Večplodne nosečnosti in posebne značilnosti parov, ki imajo težave s plodnostjo (npr. zaradi starosti ženske, določenih težav s spermo, genetske zasnove obeh staršev), so lahko povezane tudi s povečano verjetnostjo za prirojene napake pri otroku.
These side effects are not considered to be related to the use of Elonva, but to Assisted Reproductive Technology (ART) or subsequent pregnancy. 
Ti neželeni učinki ne veljajo za povezane z uporabo zdravila Elonva, ampak povezane z asistirano reprodukcijo (ART) oziroma s poznejšo nosečnostjo.
Older than 36 years 
Več kot 36 let